MedPath

Conservative Treatment of Postprostatectomy Incontinence

Not Applicable
Completed
Conditions
Urinary Incontinence
Registration Number
NCT00212264
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Brief Summary

The primary purpose of this study is to test the effectiveness, impact on quality of life, and durability of non-surgical therapies for incontinence persisting at least one year after surgery. The study is a a prospective, controlled, randomized trial comparing an 8-week, multi-component behavioral training program (pelvic floor muscle exercises, self-monitoring with bladder diaries, regular office visits, bladder control techniques, and fluid management) to the same program with the addition of biofeedback and pelvic muscle electrical stimulation.

Detailed Description

The primary purpose of this project is to test the effectiveness, impact on quality of life, and durability of conservative therapies for persistent post-prostatectomy urinary incontinence in a prospective, controlled, randomized trial comparing an 8-week, multi-component behavioral training program (pelvic floor muscle exercises, self-monitoring with bladder diaries, regular office visits, bladder control techniques, and fluid management) to the same program with the addition of biofeedback and pelvic muscle electrical stimulation.

The second purpose of the study is to examine and compare the cost-effectiveness of the 8-week, multi-component behavioral training program to the same program with the addition of biofeedback and pelvic floor electrical stimulation.

Prostate cancer is the most common internal cancer in men in the United States. The most common treatment for early disease is radical prostatectomy, the removal of the prostate gland. The two most common sequelae of prostatectomy are incontinence and erectile dysfunction. The incontinence improves and often resolves in the first year after prostatectomy, but surveys of patients show that 40% of men have incontinence severe enough to require pads 1 and 2 years after their surgery. There are currently no randomized, controlled studies of non-surgical treatments for persistent post-prostatectomy incontinence.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
208
Inclusion Criteria
  1. Involuntary loss of urine that started immediately after radical prostatectomy and has persisted for at least one year.
  2. One-week bladder diary with interpretable data and at least two incontinence episodes
Exclusion Criteria
  1. Any unstable medical condition, particularly decompensated congestive heart failure, history of malignant arrhythmias, or unstable angina
  2. Cardiac pacemaker or implanted cardiac defibrillator
  3. Current use of anticholinergic agents for detrusor instability
  4. Folstein's Mini-Mental State Exam score below 24 (impaired mental status)
  5. One-week bladder diary with continual leakage - defined as always being damp or wet or unable to quantitate individual accidents.
  6. Poorly controlled diabetes, defined as (glycosylated hemoglobin > 9 within last 3 months).
  7. Hematuria on microscopic examination. Enrollment will be permitted after urologic evaluation.
  8. Urodynamic evaluation: Post-void residual volume greater than 200 mL

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Percent Change in Incontinence Episodes on Bladder Diary2 months

\[(Baseline incontinence episodes minus 2-month incontinence episodes)/baseline incontinence episodes\] x 100%

Percent Change in Incontinence Episodes Per Week on Bladder Diary1 year

\[(Baseline incontinence episodes minus 12-month incontinence episodes)/baseline incontinence episodes\] x 100%

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.